182 related articles for article (PubMed ID: 14871245)
1. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
[TBL] [Abstract][Full Text] [Related]
2. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
[TBL] [Abstract][Full Text] [Related]
3. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
[TBL] [Abstract][Full Text] [Related]
4. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
[TBL] [Abstract][Full Text] [Related]
5. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
6. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
7. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
8. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
de Brito LR; Batey MA; Zhao Y; Squires MS; Maitland H; Leung HY; Hall AG; Jackson G; Newell DR; Irving JA
Leuk Res; 2011 Sep; 35(9):1233-40. PubMed ID: 21316102
[TBL] [Abstract][Full Text] [Related]
9. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
Trudel S; Ely S; Farooqi Y; Affer M; Robbiani DF; Chesi M; Bergsagel PL
Blood; 2004 May; 103(9):3521-8. PubMed ID: 14715624
[TBL] [Abstract][Full Text] [Related]
11. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.
Hart KC; Robertson SC; Donoghue DJ
Mol Biol Cell; 2001 Apr; 12(4):931-42. PubMed ID: 11294897
[TBL] [Abstract][Full Text] [Related]
12. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
14. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract][Full Text] [Related]
15. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
16. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.
Pollett JB; Trudel S; Stern D; Li ZH; Stewart AK
Blood; 2002 Nov; 100(10):3819-21. PubMed ID: 12393593
[TBL] [Abstract][Full Text] [Related]
18. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
19. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.
Ogata A; Chauhan D; Teoh G; Treon SP; Urashima M; Schlossman RL; Anderson KC
J Immunol; 1997 Sep; 159(5):2212-21. PubMed ID: 9278309
[TBL] [Abstract][Full Text] [Related]
20. A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells.
Choi HH; Jong HS; Park JH; Choi S; Lee JW; Kim TY; Otsuki T; Namba M; Bang YJ
Int J Oncol; 2003 Oct; 23(4):1087-93. PubMed ID: 12963989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
